0001493152-21-006001.txt : 20210315 0001493152-21-006001.hdr.sgml : 20210315 20210315161058 ACCESSION NUMBER: 0001493152-21-006001 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20210131 FILED AS OF DATE: 20210315 DATE AS OF CHANGE: 20210315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 21741593 BUSINESS ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2021

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

Commission File Number 001-14468

 

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   33-0530289
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

9669 Hermosa Avenue

Rancho Cucamonga, California

   91730
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (619) 596-8600

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
       
Non-accelerated filer [  ] Smaller reporting company [X]
       
Emerging growth company [  ]    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of March 15, 2021, there were 87,223,141 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

 

 

 

 
 

 

PURE Bioscience, Inc.

 

Form 10-Q

for the Quarterly Period Ended January 31, 2021

 

Table of Contents

 

    Page
PART I FINANCIAL INFORMATION  
Item 1. Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3. Quantitative and Qualitative Disclosures about Market Risk 20
Item 4. Controls and Procedures 21
     
PART II OTHER INFORMATION  
Item 1. Legal Proceedings 22
Item 1A. Risk Factors 22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22
Item 3. Defaults Upon Senior Securities 22
Item 4. Mine Safety Disclosures 22
Item 5. Other Information 22
Item 6. Exhibits 23
  Signatures 24

 

2
 

 

Part I - Financial Information

 

Item 1. Financial Statements

 

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

 

   January 31, 2021   July 31, 2020 
   (Unaudited)     
Assets          
Current assets          
Cash and cash equivalents  $2,927,000   $3,839,000 
Accounts receivable   466,000    1,089,000 
Inventories, net   618,000    547,000 
Restricted cash   75,000    75,000 
Prepaid expenses   29,000    16,000 
Total current assets   4,115,000    5,566,000 
Property, plant and equipment, net   771,000    316,000 
Patents, net   400,000    441,000 
Total assets  $5,286,000   $6,323,000 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $617,000   $1,344,000 
Accrued liabilities   163,000    168,000 
Total current liabilities   780,000    1,512,000 
Commitments and contingencies          
Stockholders’ equity          
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding   —    — 
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at January 31, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020   873,000    871,000 
Additional paid-in capital   127,882,000    127,414,000 
Accumulated deficit   (124,249,000)   (123,474,000)
Total stockholders’ equity   4,506,000    4,811,000 
Total liabilities and stockholders’ equity  $5,286,000   $6,323,000 

 

See accompanying notes.

 

3
 

 

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   Six Months Ended   Three months Ended 
   January 31,   January 31, 
   2021   2020   2021   2020 
Net product sales  $2,285,000   $747,000   $868,000   $349,000 
Royalty revenue   222,000    —    48,000    — 
Total revenue   2,507,000    —    916,000    — 
Cost of goods sold   1,004,000    298,000    363,000    142,000 
Gross profit   1,503,000    449,000    553,000    207,000 
Operating costs and expenses                    
Selling, general and administrative   2,100,000    2,100,000    1,054,000    810,000 
Research and development   176,000    142,000    93,000    60,000 
Total operating costs and expenses   2,276,000    2,242,000    1,147,000    870,000 
Loss from operations   (773,000)   (1,793,000)   (594,000)   (663,000)
Other income (expense)                    
Interest expense, net   (2,000)   (3,000)   (1,000)   (1,000)
Other income (expense), net   —    5,000    —    (2,000)
Total other income (expense)   (2,000)   2,000    (1,000)   (3,000)
Net loss  $(775,000)  $(1,791,000)  $(595,000)  $(666,000)
Basic and diluted net loss per share  $(0.01)  $(0.02)  $(0.01)  $(0.01)
Shares used in computing basic and diluted net loss per share   87,126,279    78,999,237    87,179,607    79,994,402 

 

See accompanying notes.

 

4
 

 

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

 

   Six Months Ended January 31, 2021   Six Months Ended January 31, 2020 
   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		 
   Shares   Amount   Capital   Deficit   Equity   Shares   Amount   Capital   Deficit   Equity 
Balances at beginning of period   87,072,951   $871,000   $127,414,000   $(123,474,000)  $  4,811,000    76,732,334   $768,000   $123,900,000   $(123,478,000)  $  1,190,000 
Issuance of common stock in private placements, net   —    —    —    —    —    2,862,068    28,000    802,000    —    830,000 
Share-based compensation expense - stock options   —    —    428,000    —    428,000    —    —    336,000    —    336,000 
Share-based compensation expense - restricted stock units   —    —    42,000    —    42,000    —    —    211,000    —    211,000 
Issuance of common stock upon the exercise of stock options   150,190    2,000    (2,000)   —    —    —    —    —    —    — 
Issuance of common stock for vested restricted stock units   —    —    —    —    —    400,000    4,000    (4,000)   —    — 
Net loss   —    —    —    (775,000)   (775,000)   —    —    —    (1,791,000)   (1,791,000)
Balances at end of period (Unaudited)   87,223,141   $873,000   $127,882,000   $(124,249,000)  $4,506,000    79,994,402   $800,000   $125,245,000   $(125,269,000)  $776,000 

 

   Three Months Ended January 31, 2021   Three Months Ended January 31, 2020 
   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		 
   Shares   Amount   Capital   Deficit   Equity   Shares   Amount   Capital   Deficit   Equity 
Balances at beginning of period (Unaudited)   87,072,951   $871,000   $127,643,000   $(123,654,000)  $      4,860,000    79,994,402   $800,000   $125,156,000   $(124,603,000)  $  1,353,000 
Share-based compensation expense - stock options   —    —    220,000    —    220,000    —    —    68,000    —    68,000 
Share-based compensation expense - restricted stock units   —    —    21,000    —    21,000    —    —    21,000    —    21,000 
Issuance of common stock upon the exercise of stock options   150,190    2,000    (2,000)   —    —    —    —    —    —    — 
Net loss   —    —    —    (595,000)   (595,000)   —    —    —    (666,000)   (666,000)
Balances at end of period (Unaudited)   87,223,141   $873,000   $127,882,000   $(124,249,000)  $4,506,000    79,994,402   $800,000   $125,245,000   $(125,269,000)  $776,000 

 

5
 

 

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   Six Months Ended 
   January 31, 
   2021   2020 
Operating activities          
Net loss  $(775,000)  $(1,791,000)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share-based compensation   470,000    547,000 
Amortization of stock issued for services   —    4,000 
Depreciation and amortization   90,000    100,000 
Changes in operating assets and liabilities:          
Accounts receivable   623,000    217,000 
Inventories   (71,000)   36,000 
Prepaid expenses   (13,000)   (1,000)
Accounts payable and accrued liabilities   (732,000)   (46,000)
Deferred rent   —    (4,000)
Net cash used in operating activities   (408,000)   (938,000)
Investing activities          
Purchases of property, plant and equipment   (504,000)   (44,000)
Net cash used in investing activities   (504,000)   (44,000)
Financing activities          
Net proceeds from the sale of common stock   —    830,000 
Net cash provided by financing activities   —    830,000 
Net decrease in cash, cash equivalents, and restricted cash   (912,000)   (152,000)
Cash, cash equivalents, and restricted cash at beginning of period   3,914,000    473,000 
Cash, cash equivalents, and restricted cash at end of period  $3,002,000   $321,000 
           
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets          
Cash and cash equivalents  $2,927,000   $246,000 
Restricted cash  $75,000   $75,000 
Total cash, cash equivalents and restricted cash  $3,002,000   $321,000 
Supplemental disclosure of non-cash activities          
Cash paid for taxes  $    $2,000 

 

See accompanying notes.

 

6
 

 

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1. Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended January 31, 2021 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2021. The July 31, 2020 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2020 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 8, 2020.

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

 

2. Liquidity

 

We have a history of recurring losses, and as of January 31, 2021 we have incurred a cumulative net loss of $124,249,000. During the six months ended January 31, 2021, we recorded a net loss of $775,000 on recorded net revenue of $2,507,000. In addition, we used $912,000 in operating and investing activities resulting in a cash balance of $2,927,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.

 

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

 

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

 

3. Significant Accounting Policies

 

Revenue Recognition

 

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

 

  1. Identify the contract with the customer
  2. Identify the performance obligations in the contract
  3. Determine the transaction price
  4. Allocate the transaction price to the performance obligations in the contract
  5. Recognize revenue when (or as) each performance obligation is satisfied

 

7
 

 

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.

 

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

 

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

 

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

 

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

 

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

 

Variable Consideration

 

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

 

8
 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

 

Net Loss Per Share

 

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,748,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

 

Inventories consist of the following:

 

   January 31, 2021   July 31, 2020 
Raw materials  $20,000   $17,000 
Finished goods   598,000    530,000 
   $618,000   $547,000 

 

9
 

 

Share-Based Compensation

 

We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

 

Impairment of Long-Lived Assets

 

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.

 

Concentrations

 

Gross product sales. For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales. For the six months ended January 31, 2021, two customers accounted for 20% and 11% of our net product sales, respectively. For the three months ended January 31, 2020, two customers accounted for 14% and 10% of our net product sales, respectively. For the six months ended January 31, 2020, two customers accounted for 17% and 10% of our net product sales, respectively.

 

Accounts receivable. As of January 31, 2021, we had accounts receivable from one customer that comprised 31% of total accounts receivable. As of January 31, 2020, we had accounts receivable from three customers that comprised of 23%, 12% and 11% of total accounts receivable, respectively.

 

Purchases. For the three months ended January 31, 2021, two vendors accounted for 18% and 16% of our purchases, respectively. For the six months ended January 31, 2021, one vendor accounted for 39% of our purchases. For the three months ended January 31, 2020, one vendor accounted for 21% of our purchases. For the six months ended January 31, 2020, one vendor accounted for 21% of our purchases.

 

Accounts payable. As of January 31, 2021, our largest two vendors accounted for 35% and 13% of the total trade accounts payable, respectively. As of January 31, 2020, our largest two vendors accounted for 14% and 12% of the total accounts payable, respectively.

 

Segments

 

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

 

4. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

 

5. Stockholders’ Equity

 

Private Placement Financing – Fiscal Year 2020

 

On October 2, 2019, we entered into and completed a closing (the “Closing”) of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares of our common stock at a purchase price of $0.29 per share, the closing sales price of our common stock on the date prior to the Closing. The Shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer.

 

The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.

 

As of January 31, 2021, the Company had 327,765 warrants outstanding with exercise prices ranging from $1.25 to $1.28. All outstanding warrants will expire on or before January 23, 2022.

 

10
 

 

6. Share-Based Compensation

 

Restricted Stock Units

 

The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.

 

During the six months ended January 31, 2021, the Company recognized $42,000 of compensation cost relating to the shares vesting during the period. During the six month period ended January 31, 2020, the Company recognized $49,000 of compensation cost relating to the shares vesting during the period. In addition, the Company accelerated the vesting of 400,000 shares of stock issued to Henry R. Lambert with a remaining value of $162,000 upon his retirement during the period. In total, the Company recognized $211,000 from the vesting of these restricted stock units.

 

Of the 2,012,500 RSUs outstanding as of January 31, 2021, 1,512,500 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

 

During the six months ended January 31, 2021 there were no Restricted Stock Units granted. As of January 31, 2021, there was $185,000 of unrecognized non-cash compensation cost related to the remaining 500,000 RSUs we expect to vest, which will be recognized over a weighted average period of 2.24 years.

 

11
 

 

A summary of our restricted stock unit activity and related data is as follows:

 

Outstanding at July 31, 2020     2,012,500  
Granted     —  
Issued     —  
Forfeited     —  
Outstanding at January 31, 2021 (of which 1,512,500 have vested and are issuable)     2,012,500  

 

Stock Option Plans

 

2007 Equity Incentive Plan

 

In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 93,000 shares available for issuance under the 2007 Plan.

 

2017 Equity Incentive Plan

 

In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 5,121,000 shares available for issuance under the 2017 Plan.

 

During the six months ended January 31, 2021, the Compensation Committee of the Board of Directors authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term.

 

A summary of our stock option activity is as follows:

 

   Shares   Weighted-
Average
Exercise
Price		   Aggregate
Intrinsic
Value		 
Outstanding at July 31, 2020   9,432,875   $0.88   $5,255,000 
Granted   60,000   $1.30    — 
Exercised   (624,375)  $0.88    170,000 
Expired   (60,000)  $0.75    33,000 
Cancelled   (400,000)  $1.19    — 
Outstanding at January 31, 2021   8,408,500   $0.87   $4,039,000 

 

The weighted-average remaining contractual term of options outstanding at January 31, 2021 was 5.0 years.

 

12
 

 

At January 31, 2021, options to purchase 7,073,500 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.90 and a weighted average remaining contractual term of 4.44 years. The total unrecognized compensation cost related to unvested stock option grants as of January 31, 2021 was approximately $385,000 and the weighted average period over which these grants are expected to vest is 0.92 years.

 

For the six months ended January 31, 2021 share-based compensation expense for stock options was $428,000. For the six months ended January 31, 2020 share-based compensation expense for stock options was $336,000.

 

During the six months ended January 31, 2021, there was a net exercise on 624,375 stock options which resulted in the issuance of 150,190 shares of our common stock. As these options were net exercised, as permitted under the respective option agreements, we did not receive any cash proceeds.

 

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

 

  

Three

Months Ended January 31, 2021

  

Three

Months Ended January 31, 2020

  

Six

Months Ended January 31, 2021

  

Six

Months Ended January 31, 2020

 
Volatility   104.93%   79.48%   104.93.%   79.62%
Risk-free interest rate   0.18%   1.46%   0.18%   1.43%
Dividend yield   0.0%   0.0%   0.0%   0.0%
Expected life   2.81 years    5.50    2.81 years    5.57 years 

 

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

 

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

 

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

 

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

 

7. Related Party Transactions

 

As of January 31, 2021 and January 31, 2020, accounts payable include $64,047 and $120,000 in board fees due to officers and directors, respectively.

 

8. Commitments and Contingencies

 

The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

 

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

 

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

 

13
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

 

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Overview

 

We are focused on developing and commercializing proprietary antimicrobial products that provide safe and cost-effective solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, we believe SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, non-causticity and the inability of bacteria to form a resistance to it.

 

We believe there is a significant market opportunity for our safe, non-toxic, non-caustic and effective SDC-based solutions. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. In addition to our direct sales efforts with PURE Hard Surface and PURE Control, we market and sell our SDC-based products indirectly through third-party distributors supporting various industries.

 

14
 

 

Business Strategy

 

Our goal is to become a sustainable company by commercializing the SDC-based products we have developed with our proprietary technology platform. We are focused on delivering leading antimicrobial products that address food safety risks across the food industry supply chain. Key aspects of our business strategy include:

 

  ● Expanding sales and distribution for our products into the food industry with a focus on a dual track of food safety market opportunities:

 

    ● Hard Surface Disinfectant - commercializing our current EPA registered PURE Hard Surface disinfectant and sanitizer for use in foodservice operations, food manufacturing and food transportation.
       
    ● Direct Food Contact - commercializing FDA approved PURE Control as a direct food contact processing aid for fresh produce; commercializing FDA approved PURE Control as a food processing and intervention aid for food processors treating raw poultry in pre and post on-line reprocessing.

 

  ● Continuing to grow and establish new strategic alliances to maximize the commercial potential of our technology platform;
     
  ● Continuing to partner with third parties who are seeking, or intend to seek, approvals to market SDC-based products in markets outside the U.S.
     
  ● Developing additional proprietary products and applications; and
     
  ● Protecting and enhancing our intellectual property.

 

In addition to our current products addressing food safety, we intend to leverage our technology platform through licensing and distribution collaborations in order to develop new products and enter into new markets that could potentially generate multiple sources of revenue.

 

Financial Overview

 

This financial overview provides a general description of our revenue and expenses.

 

Net Product Sales

 

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue. See “Critical Accounting Policies and Estimates – Revenue Recognition”.

 

Cost of Goods Sold

 

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

 

15
 

 

Selling, General and Administrative

 

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

 

Research and Development

 

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

 

Other Income (Expense)

 

We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) in our consolidated statements of operations.

 

COVID-19

 

The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

 

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

 

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

 

16
 

 

Results of Operations

 

Fluctuations in Operating Results

 

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.

 

Comparison of the Three Months Ended January 31, 2021 and 2020

 

Net Product Sales

 

Net product sales were $868,000 and $349,000 for the three months ended January 31, 2021 and 2020, respectively. The increase of $519,000 was attributable to increased sales across our distribution and end-user network servicing the food processing, transportation and janitorial industry. Our top three customers accounted for $356,000 of net product sales for the three months ended January 31, 2021.

 

For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

 

For the three months ended January 31, 2020, two individual customers accounted for 14% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

 

During the three months ended January 31, 2021, we recognized $48,000 in royalties from a nonexclusive third-party distributor.

 

Cost of Goods Sold

 

Cost of goods sold was $363,000 and $142,000 for the three months ended January 31, 2021 and 2020, respectively. The increase of $221,000 was primarily attributable to increased product sales.

 

Gross margin as a percentage of net product sales, or gross margin percentage, was 58% and 59% for the three months ended January 31, 2021 and 2020, respectively. The decrease in gross margin percentage was primarily attributable to the sale of lower margin formulations and packaging configurations of our products during the quarter ended January 31, 2021, as compared with the prior period.

 

Selling, General and Administrative Expense

 

Selling, general and administrative expense was $1,054,000 and $810,000 for the three months ended January 31, 2021 and 2020, respectively. The increase of $244,000 was primarily attributable to increased personnel and facility costs, as well as, share-based compensation.

 

Share-based compensation expense, included in selling, general and administrative expense, was $241,000 and $89,000 for the three months ended January 31, 2021 and 2020, respectively. The increase of $152,000 is primarily due to the current year vesting of stock options and restricted stock units granted in the prior year.

 

Research and Development Expense

 

Research and development expense, primarily consisting of third-party fees and personnel costs, was $93,000 and $60,000 for the three months ended January 31, 2021 and 2020, respectively.

 

Comparison of the Six Months Ended January 31, 2021 and 2020

 

Net Product Sales

 

Net product sales were $2,285,000 and $747,000 for the six months ended January 31, 2021 and 2020, respectively. The increase of $1,538,000 was attributable to increased sales across our distribution and end-user network servicing the food processing, transportation and janitorial industry. Our top two customers accounted for $700,000 of net product sales for the six months ended January 31, 2021.

 

For the six months ended January 31, 2021, two individual customers accounted for 20% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

 

For the six months ended January 31, 2020, two individual customers accounted for 17% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

 

During the six months ended January 31, 2021, we recognized $222,000 in royalties from a nonexclusive third-party distributor.

 

Cost of Goods Sold

 

Cost of goods sold was $1,004,000 and $298,000 for the six months ended January 31, 2021 and 2020, respectively. The increase of $706,000 was primarily attributable to increased product sales.

 

Gross margin as a percentage of net product sales, or gross margin percentage, was 56% and 60% for the six months ended January 31, 2021 and 2020, respectively. The decrease in gross margin percentage was primarily attributable to the sale of lower margin formulations and packaging configurations of our products during the six months ended January 31, 2021, as compared with the prior period.

 

Selling, General and Administrative Expense

 

Selling, general and administrative expense was $2,100,000 for the six months ended January 31, 2021 and 2020. During the six months ended January 31, 2021 versus 2020, personnel and facility costs increased offset by reduced legal and professional service costs.

 

Share-based compensation expense, included in selling, general and administrative expense, was $470,000 and $547,000 for the six months ended January 31, 2021 and 2020, respectively. The decrease of $77,000 is primarily due to the prior year accelerated vesting of stock options and restricted stock units held by Henry R. Lambert, the former Chief Executive Officer.

 

Research and Development Expense

 

Research and development expense was $176,000 and $142,000 for the six months ended January 31, 2020 and 2019, respectively. The increase of $34,000 was primarily attributable to increased spending on third-party research.

 

17
 

 

Liquidity and Capital Resources

 

As of January 31, 2021, we had $3,002,000 in cash and cash equivalents compared with $3,914,000 in cash and cash equivalents as of July 31, 2020. The net decrease in cash and cash equivalents was primarily attributable to cash used to fund operations and investments in property, plant and equipment. Additionally, as of January 31, 2021, we had $780,000 of current liabilities, including $617,000 in accounts payable, compared with $1,512,000 of current liabilities, including $1,344,000 in accounts payable as of July 31, 2020. The net decrease in current liabilities was primarily due to trade payables due to our contract manufacture.

 

We have a history of recurring losses, and as of January 31, 2021 we have incurred a cumulative net loss of $124,249,000. During the six months ended January 31, 2021, we recorded a net loss of $775,000 on recorded net revenue of $2,507,000. In addition, we used $912,000 in operating and investing activities resulting in a cash balance of $2,927,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.

 

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

 

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. Our financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

 

18
 

 

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

 

Revenue Recognition

 

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

 

  1. Identify the contract with the customer
  2. Identify the performance obligations in the contract
  3. Determine the transaction price
  4. Allocate the transaction price to the performance obligations in the contract
  5. Recognize revenue when (or as) each performance obligation is satisfied

 

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.

 

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

 

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

 

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

 

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

 

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

 

Variable Consideration

 

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

 

19
 

 

Share-Based Compensation

 

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

 

Impairment of Long-Lived Assets

 

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.

 

Recent Accounting Pronouncements

 

See Note 4 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

 

Off Balance Sheet Arrangements

 

We do not have any off balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

 

20
 

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

 

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

 

Changes in Internal Control Over Financial Reporting

 

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the six months ended January 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

21
 

 

PART II – Other Information

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

 

Item 1A. Risk Factors

 

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2020, which we filed with the SEC on October 8, 2020 (the “Form 10-K”). Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

 

Risks Related to Our Business and Industry

 

The currently evolving situation related to the COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

 

The global outbreak of COVID-19 has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

 

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

 

The extent to which the COVID-19 outbreak ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 outbreak has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None.

 

22
 

 

Item 6. Exhibits

 

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

 

3.1   Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)
     
3.1.1   Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)
     
3.2   Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)
     
3.2.1   Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)
     
31.1 *   Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2 *   Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1 *   Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2 *   Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101 *   The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended January 31, 2021, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at January 31, 2021 and July 31, 2020; (ii) Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2021 and 2020; (iii) Condensed Consolidated Statements of Stockholders’ equity for the three and six months ended January 31, 2021 and 2020 ;(iv) Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2021 and 2020; and (v) Notes to Condensed Consolidated Financial Statements.
     
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

 

23
 

 

Signatures

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PURE BIOSCIENCE, INC.
     
Date: March 15, 2021 By: /s/ TOM Y. LEE
   

Tom Y. Lee, Chief Executive Officer

(Principal Executive Officer)

     
Date: March 15, 2021 By: /s/ MARK S. ELLIOTT
    Mark S. Elliott, Vice President, Finance
    (Principal Financial and Accounting Officer)

 

24

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Tom Y. Lee, Chief Executive Officer of PURE Bioscience, Inc., certify that:

 

1. I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 15, 2021 By: /s/ Tom Y. Lee
    Tom Y. Lee
    Chief Executive Officer
    (Principal Executive Officer)

 

 
 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Mark S. Elliott, Vice President, Finance and Principal Financial and Accounting Officer of PURE Bioscience, Inc., certify that:

 

1. I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 15, 2021 By: /s/ MARK S. ELLIOTT
    Mark S. Elliott
    Vice President, Finance
    (Principal Financial and Accounting Officer)

 

 
 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

 

  (i) the accompanying report on Form 10-Q of the Company for the period ended January 31, 2021, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
     
  (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 15, 2021 By: /s/ Tom Y. Lee
   

Tom Y. Lee

Chief Executive Officer

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

 

  (i) the accompanying report on Form 10-Q of the Company for the period ended January 31, 2021, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
     
  (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 15, 2021 By: /s/ Mark S. Elliott
   

Mark S. Elliott

Vice President, Finance

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 

 

 EX-101.INS 6 pure-20210131.xml XBRL INSTANCE FILE 0001006028 2019-07-31 0001006028 2020-08-01 2021-01-31 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001006028 us-gaap:CommonStockMember 2019-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001006028 us-gaap:RetainedEarningsMember 2019-07-31 0001006028 2020-07-31 0001006028 us-gaap:CommonStockMember 2020-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001006028 us-gaap:RetainedEarningsMember 2020-01-31 0001006028 us-gaap:PrivatePlacementMember 2019-10-01 2019-10-02 0001006028 us-gaap:PrivatePlacementMember 2019-10-02 0001006028 us-gaap:PrivatePlacementMember PURE:TomYLeeMember 2019-10-02 0001006028 us-gaap:PrivatePlacementMember PURE:DaleOkunoMember 2019-10-02 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:SharesVestedDuringPeriodMember 2019-08-01 2020-01-31 0001006028 us-gaap:CommonStockMember 2019-08-01 2020-01-31 0001006028 us-gaap:CommonStockMember 2019-11-01 2020-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2020-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0001006028 us-gaap:RetainedEarningsMember 2019-08-01 2020-01-31 0001006028 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0001006028 2019-10-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2019-11-01 2020-01-31 0001006028 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember PURE:CustomerOneMember 2019-11-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerOneMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerThreeMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorOneMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorTwoMember 2019-08-01 2020-01-31 0001006028 us-gaap:CommonStockMember 2020-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001006028 us-gaap:RetainedEarningsMember 2020-07-31 0001006028 2020-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-07-31 0001006028 2021-01-31 0001006028 2019-08-01 2020-01-31 0001006028 us-gaap:CommonStockMember 2020-08-01 2021-01-31 0001006028 us-gaap:CommonStockMember 2021-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2021-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001006028 us-gaap:RetainedEarningsMember 2020-08-01 2021-01-31 0001006028 us-gaap:RetainedEarningsMember 2021-01-31 0001006028 us-gaap:ProductMember 2020-08-01 2021-01-31 0001006028 us-gaap:ProductMember 2019-08-01 2020-01-31 0001006028 us-gaap:RoyaltyMember 2019-08-01 2020-01-31 0001006028 us-gaap:RoyaltyMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerOneMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerOneMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:TwoCustomersMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:OneCustomerMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2019-08-01 2020-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorOneMember 2020-08-01 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-08-01 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:ConsultantsAndOthersMember 2020-08-01 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:SharesVestedDuringPeriodMember 2020-08-01 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:HenryRLambertMember 2020-08-01 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:VestedAndIssuableMember 2020-08-01 2021-01-31 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2021-01-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2020-08-01 2021-01-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-01-31 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2021-01-31 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2020-01-31 0001006028 2021-03-15 0001006028 us-gaap:ProductMember 2020-11-01 2021-01-31 0001006028 us-gaap:ProductMember 2019-11-01 2020-01-31 0001006028 us-gaap:RoyaltyMember 2020-11-01 2021-01-31 0001006028 us-gaap:RoyaltyMember 2019-11-01 2020-01-31 0001006028 2020-11-01 2021-01-31 0001006028 2019-11-01 2020-01-31 0001006028 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001006028 us-gaap:CommonStockMember 2020-10-31 0001006028 us-gaap:CommonStockMember 2019-10-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001006028 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001006028 us-gaap:RetainedEarningsMember 2020-10-31 0001006028 us-gaap:RetainedEarningsMember 2019-10-31 0001006028 2020-10-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerOneMember 2020-11-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerTwoMember 2020-11-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerThreeMember 2020-11-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2020-11-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorTwoMember 2020-11-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2019-11-01 2020-01-31 0001006028 PURE:ConsultantMember 2021-01-31 0001006028 PURE:ConsultantMember 2020-08-01 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorTwoMember 2020-08-01 2021-01-31 0001006028 srt:MinimumMember 2021-01-31 0001006028 srt:MaximumMember 2021-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0.01 0.01 5000000 5000000 0.01 0.01 150000000 150000000 PURE BIOSCIENCE, INC. 10-Q 2021-01-31 false Non-accelerated Filer 0001006028 --07-31 2100000 2100000 1054000 810000 176000 142000 93000 60000 2276000 2242000 1147000 870000 -773000 -1793000 -594000 -663000 5000 -2000 -2000 2000 -1000 -3000 -775000 -1791000 -666000 -1791000 -775000 -595000 -666000 -595000 87223141 true false 2021 428000 336000 68000 336000 428000 220000 68000 220000 42000 211000 21000 211000 42000 21000 21000 21000 473000 3914000 321000 3002000 3839000 246000 2927000 Yes Yes false Q2 1344000 617000 64047 120000 2000 3000 1000 1000 75000 75000 321000 3002000 76732334 79994402 87072951 87223141 87072951 79994402 1190000 768000 123900000 -123478000 4811000 800000 125245000 -125269000 1353000 871000 127414000 -123474000 776000 4506000 873000 127882000 -124249000 871000 800000 127643000 125156000 -123654000 -124603000 4860000 830000 28000 802000 830000 2862068 2862068 150190 1503000 449000 553000 207000 -0.01 -0.02 -0.01 -0.01 87126279 78999237 87179607 79994402 4000 -4000 400000 1004000 298000 363000 142000 150190 150190 2507000 2285000 747000 222000 868000 349000 48000 916000 87072951 87223141 87072951 87223141 6323000 5286000 441000 400000 316000 771000 5566000 4115000 16000 29000 75000 75000 547000 618000 1089000 466000 1512000 780000 168000 163000 6323000 5286000 -123474000 -124249000 127414000 127882000 871000 873000 2000 -2000 2000 -2000 -912000 -152000 830000 830000 -504000 -44000 504000 44000 -408000 -938000 -4000 -732000 -46000 13000 1000 71000 -36000 -623000 -217000 90000 100000 4000 470000 547000 2000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1. Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to &#8220;PURE,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; refer to PURE Bioscience, Inc. and our wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended January 31, 2021 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2021. The July 31, 2020 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2020 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 8, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Liquidity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a history of recurring losses, and as of January 31, 2021 we have incurred a cumulative net loss of $124,249,000. During the six months ended January 31, 2021, we recorded a net loss of $775,000 on recorded net revenue of $2,507,000. In addition, we used $912,000 in operating and investing activities resulting in a cash balance of $2,927,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. Significant Accounting Policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Revenue Recognition</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">1.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Identify the contract with the customer</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">2.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Identify the performance obligations in the contract</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">3.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Determine the transaction price</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">4.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Allocate the transaction price to the performance obligations in the contract</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">5.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Recognize revenue when (or as) each performance obligation is satisfied</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE<sup>&#174;</sup> Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control<sup>&#174;</sup> as a direct food contact processing aid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer&#8217;s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s licensing contracts typically provide for royalties based on the licensee&#8217;s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Variable Consideration</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Use of Estimates</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Net Loss Per Share</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,748,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Inventory</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January 31, 2021</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>July 31, 2020</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Raw materials</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">20,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">17,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Finished goods</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">598,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">530,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">618,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">547,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Share-Based Compensation</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Impairment of Long-Lived Assets</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Concentrations</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Gross product sales</i>. For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales. For the six months ended January 31, 2021, two customers accounted for 20% and 11% of our net product sales, respectively. For the three months ended January 31, 2020, two customers accounted for 14% and 10% of our net product sales, respectively. For the six months ended January 31, 2020, two customers accounted for 17% and 10% of our net product sales, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts receivable. </i>As of January 31, 2021, we had accounts receivable from one customer that comprised 31% of total accounts receivable. As of January 31, 2020, we had accounts receivable from three customers that comprised of 23%, 12% and 11% of total accounts receivable, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Purchases. </i>For the three months ended January 31, 2021, two vendors accounted for 18% and 16% of our purchases, respectively. For the six months ended January 31, 2021, one vendor accounted for 39% of our purchases. For the three months ended January 31, 2020, one vendor accounted for 21% of our purchases. For the six months ended January 31, 2020, one vendor accounted for 21% of our purchases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts payable.</i> As of January 31, 2021, our largest two vendors accounted for 35% and 13% of the total trade accounts payable, respectively. As of January 31, 2020, our largest two vendors accounted for 14% and 12% of the total accounts payable, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Segments</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We operate in one segment for the manufacture and distribution of our products. In accordance with the &#8220;Segment Reporting&#8221; Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under &#8220;Segment Reporting&#8221; due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by &#8220;Segment Reporting&#8221; can be found in the accompanying financial statements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>4. Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, <i>Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (&#8220;CECL&#8221;) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>5. Stockholders&#8217; Equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Private Placement Financing &#8211; Fiscal Year 2020</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 2, 2019, we entered into and completed a closing (the &#8220;Closing&#8221;) of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares of our common stock at a purchase price of $0.29 per share, the closing sales price of our common stock on the date prior to the Closing. The Shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company&#8217;s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company&#8217;s President and Chief Executive Officer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of January 31, 2021, the Company had 327,765 warrants outstanding with exercise prices ranging from $1.25 to $1.28. All outstanding warrants will expire on or before January 23, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>6. Share-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Restricted Stock Units</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues restricted stock unit awards (&#8220;RSUs&#8221;) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended January 31, 2021, the Company recognized $42,000 of compensation cost relating to the shares vesting during the period. During the six month period ended January 31, 2020, the Company recognized $49,000 of compensation cost relating to the shares vesting during the period. In addition, the Company accelerated the vesting of 400,000 shares of stock issued to Henry R. Lambert with a remaining value of $162,000 upon his retirement during the period. In total, the Company recognized $211,000 from the vesting of these restricted stock units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the 2,012,500 RSUs outstanding as of January 31, 2021, 1,512,500 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as &#8220;for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee&#8217;s Service ceases for any reason and such cessation constitutes a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code; (iii) the date of Grantee&#8217;s death or (iv) the date of a Change in Control that constitutes a &#8220;change in control event&#8221; within the meaning of Section 409A of the Code&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended January 31, 2021 there were no Restricted Stock Units granted. As of January 31, 2021, there was $185,000 of unrecognized non-cash compensation cost related to the remaining 500,000 RSUs we expect to vest, which will be recognized over a weighted average period of 2.24 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%"><font style="font-size: 10pt">Outstanding at July 31, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">2,012,500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Issued</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Forfeited</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Outstanding at January 31, 2021 (of which 1,512,500 have vested and are issuable)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,012,500</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Stock Option Plans</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>2007 Equity Incentive Plan</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (&#8220;2007 Plan&#8221;), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 93,000 shares available for issuance under the 2007 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>2017 Equity Incentive Plan</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (&#8220;2017 Plan&#8221;), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 5,121,000 shares available for issuance under the 2017 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended January 31, 2021, the Compensation Committee of the Board of Directors authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of our stock option activity is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted-<br /> Average<br /> Exercise <br /> Price</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Aggregate<br /> Intrinsic<br /> Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%"><font style="font-size: 10pt">Outstanding at July 31, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9,432,875</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.88</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5,255,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(624,375</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.88</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">170,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Expired</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(60,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.75</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">33,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(400,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.19</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at January 31, 2021</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,408,500</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.87</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,039,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average remaining contractual term of options outstanding at January 31, 2021 was 5.0 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At January 31, 2021, options to purchase 7,073,500 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.90 and a weighted average remaining contractual term of 4.44 years. The total unrecognized compensation cost related to unvested stock option grants as of January 31, 2021 was approximately $385,000 and the weighted average period over which these grants are expected to vest is 0.92 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended January 31, 2021 share-based compensation expense for stock options was $428,000. For the six months ended January 31, 2020 share-based compensation expense for stock options was $336,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended January 31, 2021, there was a net exercise on 624,375 stock options which resulted in the issuance of 150,190 shares of our common stock. As these options were net exercised, as permitted under the respective option agreements, we did not receive any cash proceeds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Volatility</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">104.93</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">79.48</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">104.93.</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">79.62</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Risk-free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.18</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.46</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.18</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.43</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected life</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.81 years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.81 years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.57 years</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected life of options was estimated using the average between the contractual term and the vesting term of the options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7. Related Party Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of January 31, 2021 and January 31, 2020, accounts payable include $64,047 and $120,000 in board fees due to officers and directors, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Revenue Recognition</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">1.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Identify the contract with the customer</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">2.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Identify the performance obligations in the contract</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">3.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Determine the transaction price</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">4.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Allocate the transaction price to the performance obligations in the contract</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">5.</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Recognize revenue when (or as) each performance obligation is satisfied</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE<sup>&#174;</sup> Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control<sup>&#174;</sup> as a direct food contact processing aid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer&#8217;s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s licensing contracts typically provide for royalties based on the licensee&#8217;s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Variable Consideration</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Use of Estimates</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Net Loss Per Share</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,748,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Inventory</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January 31, 2021</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>July 31, 2020</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Raw materials</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">20,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">17,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Finished goods</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">598,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">530,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">618,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">547,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Share-Based Compensation</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Impairment of Long-Lived Assets</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Concentrations</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Gross product sales</i>. For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales. For the six months ended January 31, 2021, two customers accounted for 20% and 11% of our net product sales, respectively. For the three months ended January 31, 2020, two customers accounted for 14% and 10% of our net product sales, respectively. For the six months ended January 31, 2020, two customers accounted for 17% and 10% of our net product sales, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts receivable. </i>As of January 31, 2021, we had accounts receivable from one customer that comprised 31% of total accounts receivable. As of January 31, 2020, we had accounts receivable from three customers that comprised of 23%, 12% and 11% of total accounts receivable, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Purchases. </i>For the three months ended January 31, 2021, two vendors accounted for 18% and 16% of our purchases, respectively. For the six months ended January 31, 2021, one vendor accounted for 39% of our purchases. For the three months ended January 31, 2020, one vendor accounted for 21% of our purchases. For the six months ended January 31, 2020, one vendor accounted for 21% of our purchases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts payable.</i> As of January 31, 2021, our largest two vendors accounted for 35% and 13% of the total trade accounts payable, respectively. As of January 31, 2020, our largest two vendors accounted for 14% and 12% of the total accounts payable, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Segments</u></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We operate in one segment for the manufacture and distribution of our products. In accordance with the &#8220;Segment Reporting&#8221; Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under &#8220;Segment Reporting&#8221; due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by &#8220;Segment Reporting&#8221; can be found in the accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January 31, 2021</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>July 31, 2020</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Raw materials</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">20,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">17,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Finished goods</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">598,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">530,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">618,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">547,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%"><font style="font-size: 10pt">Outstanding at July 31, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">2,012,500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Issued</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Forfeited</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Outstanding at January 31, 2021 (of which 1,512,500 have vested and are issuable)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,012,500</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of our stock option activity is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted-<br /> Average<br /> Exercise <br /> Price</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Aggregate<br /> Intrinsic<br /> Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%"><font style="font-size: 10pt">Outstanding at July 31, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9,432,875</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.88</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5,255,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(624,375</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.88</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">170,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Expired</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(60,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.75</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">33,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(400,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.19</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at January 31, 2021</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,408,500</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.87</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,039,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock options was estimated at the grant date using the following weighted average assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Months Ended January 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Volatility</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">104.93</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">79.48</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">104.93.</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">79.62</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Risk-free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.18</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.46</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.18</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.43</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected life</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.81 years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.81 years</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.57 years</font></td> <td>&#160;</td></tr> </table> 10748765 10410890 0.10 0.14 0.17 0.10 0.11 0.14 0.12 0.20 0.11 0.31 0.12 0.23 0.39 0.21 0.35 0.15 0.14 0.12 0.18 0.16 0.21 0.13 17000 20000 530000 598000 0.29 290000 250000 830000 P11M1D P10Y P2Y P10Y P10Y 49000 211000 42000 162000 400000 2012500 500000 1512500 1512500 These RSUs are issued upon settlement date which is defined as "for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code". 385000 185000 P2Y2M27D P5Y 4000000 2026-02-04 2031-01-31 93000 5121000 5000000 60000 48000 The options vest quarterly over one year and carry a five year term. 7073500 624375 0.90 P4Y5M9D 428000 336000 2012500 2012500 9432875 8408500 60000 60000 400000 0.88 0.87 1.30 0.88 0.75 1.19 5255000 4039000 170000 33000 1.0493 0.7962 1.0493 0.7948 0.0018 0.0143 0.0018 0.0146 0.00 0.00 0.00 0.00 P2Y9M22D P5Y6M25D P2Y9M22D P5Y6M 327765 1.25 1.28 2022-01-23 EX-101.SCH 7 pure-20210131.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Share-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pure-20210131_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 pure-20210131_def.xml XBRL DEFINITION FILE EX-101.LAB 10 pure-20210131_lab.xml XBRL LABEL FILE Plan Name [Axis] 2007 Equity Incentive Plan [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Sale of Stock [Axis] Private Placement [Member] Title of Individual [Axis] Tom Y Lee [Member] Dale Okuno [Member] Award Type [Axis] Restricted Stock Unit Awards (RSU's) [Member] Vesting [Axis] Shares Vested During Period [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Net Product Sales [Member] Customer [Axis] Customer Two [Member] Customer One [Member] Accounts Receivable [Member] Customer Three [Member] Accounts Payable [Member] Vendor One [Member] Vendor Two [Member] Product and Service [Axis] Net Product Sales [Member] Royalty Revenue [Member] Customer Two [Member] Customer One [Member] Purchases [Member] Related Party Transaction [Axis] Consultants and Others [Member] Henry R. Lambert [Member] Scenario [Axis] Vested and Issuable [Member] 2017 Equity Incentive Plan [Member] Board Fees due to Officers and Directors [Member] Individual Customer One [Member] Individual Customer Two [Member] Individual Customer Three [Member] Consultant [Member] Range [Axis] Minimum [Member] Maximum [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Inventories, net Restricted cash Prepaid expenses Total current assets Property, plant and equipment, net Patents, net Total assets Liabilities and stockholders' equity Current liabilities Accounts payable Accrued liabilities Total current liabilities Commitments and contingencies Stockholders' equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at January 31, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Total revenue Cost of goods sold Gross profit Operating costs and expenses Selling, general and administrative Research and development Total operating costs and expenses Loss from operations Other income (expense) Interest expense, net Other income (expense), net Total other income (expense) Net loss Basic and diluted net loss per share Shares used in computing basic and diluted net loss per share Balance Balance, shares Issuance of common stock in private placements, net Issuance of common stock in private placements, net, shares Share-based compensation expense - stock options Share-based compensation expense - restricted stock units Issuance of common stock upon the exercise of stock options Issuance of common stock upon the exercise of stock options, shares Issuance of common stock for vested restricted stock units Issuance of common stock for vested restricted stock units, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Amortization of stock issued for services Depreciation and amortization Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable and accrued liabilities Deferred rent Net cash used in operating activities Investing activities Purchases of property, plant and equipment Net cash used in investing activities Financing activities Net proceeds from the sale of common stock Net cash provided by financing activities Net decrease in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash and cash equivalents Restricted cash Total cash, cash equivalents and restricted cash Supplemental disclosure of non-cash activities Cash paid for taxes Accounting Policies [Abstract] Basis of Presentation Liquidity Liquidity Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Share-based Payment Arrangement [Abstract] Share-Based Compensation Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Revenue Recognition Use of Estimates Net Loss Per Share Inventory Share-Based Compensation Impairment of Long-Lived Assets Concentrations Segments Schedule of Inventories Schedule of Restricted Stock Activity Schedule of Stock Option Activity Schedule of Fair Value Assumptions Cumulative net loss Net income (loss) Revenue Cash balance Dilutive common share Impairment of long-lived assets Concentration risk percentage Raw materials Finished goods Inventory, net Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Statistical Measurement [Axis] Value of common stock shares Number of common stock shares issued Price per share Investments amount Proceeds from issuance of private placement Number of warrants outstanding Warrant exercise price Warrant expiration date Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation, vesting period Compensation cost recognized Stock issued during period, shares, share-based compensation Number of units, unvested Number of units, vested Restricted stock units vested description Number of units, granted Unrecognized non-cash compensation costs Weighted-average contractual term of expected to vest Common stock shares increase under the plan Share-based compensation, expiration date Number of shares available for issuance under the plan Common stock, shares reserved Number of stock option authorized for issuance Fair value of stock option Terms of award Options issued to purchase common stock exercisable Weighted average exercise price Weighted average contractual term Share-based compensation Outstanding, Beginning balance Granted Issued Forfeited Outstanding, Ending balance Number of units, vested and issuable Options Outstanding Shares, Beginning Balance Options Granted, Shares Options Exercised, Shares Options Expired, Shares Options Cancelled, Shares Options Outstanding Shares, Ending Balance Weighted- Average Exercise Price Outstanding, Beginning Balance Weighted- Average Exercise Price Granted Weighted- Average Exercise Price Exercised Weighted- Average Exercise Price Expired Weighted- Average Exercise Price Cancelled Weighted- Average Exercise Price Outstanding, Ending Balance Aggregate Intrinsic Value Outstanding, Beginning Balance Aggregate Intrinsic Value Outstanding, Exercised Aggregate Intrinsic Value Outstanding, Expired Aggregate Intrinsic Value Outstanding, Ending Balance Volatility Risk-free interest rate Dividend yield Expected life Accounts Payable [Member] Amortization of stock issued for services. Board of Directors [Member] Business Development Activities [Member] Business Development Services [Member] Carried Forward Indefinitely [Member] Consultants and Others [Member] Customer One [Member] Customer Three [Member] Customer Two [Member] Dale Okuno [Member] Dave Pfanzelter [Member] Employees, Directors and Consultants [Member] Employees, Officers and Directors [Member] Federal [Member] Garden State Securities Inc [Member] General Financial Advisory Services [Member] Henry R. Lambert [Member] Individual Customer One [Member] Individual Customer Three [Member] Individual Customer Two [Member] ICC [Member] Investors [Member] Ivan Chen [Member] Manufacturing Supply Agreement [Member] Mr. Tom Y. Lee [Member] Officers and Directors [Member] One Customer [Member] Original Warrants [Member] Other Individual Customer [Member] Pfanzelter [Member] Promissory Note [Member] Shares Vested During Period [Member] State [Member] Sublease Agreement [Member] SwabPlus L.P. [Member] SwabPlus Inc [Member] Third-Party Warehouse Fire [Member] Three Customer [Member] Tom Myers [Member] Tom Y. Lee [Member] Two Customer [Member] Two Customers [Member] Two Individual Customer [Member] 2007 Equity Incentive Plan [Member] 2015 Private Placement Financing [Member] 2015 Warrants [Member] 2015 Warrants [Member] 2014 Warrants [Member] 2017 Equity Incentive Plan [Member] 2017 Warrants [Member] Two Year Service Agreement [Member] Vendor One [Member] Vendor Two [Member] Warrant 5 [Member] Warrant 4 [Member] Warrant Liability [Member] Warrant 1 [Member] Warrant 3 [Member] Warrant 2 [Member] Accredited Investors [Member] Net Proceeds After Expenses Deductions [Member] Three Holders [Member] Contract Manufacturer [Member] Purchases [Member] Harmony Bioscience, Inc [Member] Previously Utilized [Member] One Individual Customer [Member] Three Individual Customer [Member] No Other Individual Customer [Member] Individual Customer [Member] Foreign [Member] Computers and Equipment [Member] Mr. Myers [Member] May, June and July of 2019 [Member] Messrs. Dale Okuno [Member] Vested and Issuable [Member] Board Fees due to Officers and Directors [Member] Exercise Price 1 [Member] Exercise Price 2 [Member] Exercise Price 3 [Member] Issuance of common stock for vested restricted stock units Issuance of common stock for vested restricted stock units, shares. Liquidity [Text Block] Consultant [Member] Restricted stock units vested description. Net number of non-option equity instruments issued to participants. Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, expired, aggregate intrinsic value. Warrant expiration date. Product [Member] TwoCustomersMember OneCustomerMember Assets, Current Assets [Default Label] Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Liquidity [Text Block] Share-based Payment Arrangement [Policy Text Block] Share-based Payment Arrangement, Expense Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value EX-101.PRE 11 pure-20210131_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - shares
 6 Months Ended
Jan. 31, 2021
Mar. 15, 2021
Cover [Abstract]    
Entity Registrant Name PURE BIOSCIENCE, INC.  
Entity Central Index Key 0001006028  
Document Type 10-Q  
Document Period End Date Jan. 31, 2021  
Amendment Flag false  
Current Fiscal Year End Date --07-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   87,223,141
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2021  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Balance Sheets - USD ($)
Jan. 31, 2021
Jul. 31, 2020
Current assets    
Cash and cash equivalents $ 2,927,000 $ 3,839,000
Accounts receivable 466,000 1,089,000
Inventories, net 618,000 547,000
Restricted cash 75,000 75,000
Prepaid expenses 29,000 16,000
Total current assets 4,115,000 5,566,000
Property, plant and equipment, net 771,000 316,000
Patents, net 400,000 441,000
Total assets 5,286,000 6,323,000
Current liabilities    
Accounts payable 617,000 1,344,000
Accrued liabilities 163,000 168,000
Total current liabilities 780,000 1,512,000
Commitments and contingencies
Stockholders' equity    
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at January 31, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020 873,000 871,000
Additional paid-in capital 127,882,000 127,414,000
Accumulated deficit (124,249,000) (123,474,000)
Total stockholders' equity 4,506,000 4,811,000
Total liabilities and stockholders' equity $ 5,286,000 $ 6,323,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jan. 31, 2021
Jul. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 87,223,141 87,072,951
Common stock, shares outstanding 87,223,141 87,072,951
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Total revenue $ 916,000 $ 2,507,000
Cost of goods sold 363,000 142,000 1,004,000 298,000
Gross profit 553,000 207,000 1,503,000 449,000
Operating costs and expenses        
Selling, general and administrative 1,054,000 810,000 2,100,000 2,100,000
Research and development 93,000 60,000 176,000 142,000
Total operating costs and expenses 1,147,000 870,000 2,276,000 2,242,000
Loss from operations (594,000) (663,000) (773,000) (1,793,000)
Other income (expense)        
Interest expense, net (1,000) (1,000) (2,000) (3,000)
Other income (expense), net (2,000) 5,000
Total other income (expense) (1,000) (3,000) (2,000) 2,000
Net loss $ (595,000) $ (666,000) $ (775,000) $ (1,791,000)
Basic and diluted net loss per share $ (0.01) $ (0.01) $ (0.01) $ (0.02)
Shares used in computing basic and diluted net loss per share 87,179,607 79,994,402 87,126,279 78,999,237
Net Product Sales [Member]        
Total revenue $ 868,000 $ 349,000 $ 2,285,000 $ 747,000
Royalty Revenue [Member]        
Total revenue $ 48,000 $ 222,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Jul. 31, 2019 $ 768,000 $ 123,900,000 $ (123,478,000) $ 1,190,000
Balance, shares at Jul. 31, 2019 76,732,334      
Issuance of common stock in private placements, net $ 28,000 802,000 830,000
Issuance of common stock in private placements, net, shares 2,862,068      
Share-based compensation expense - stock options 336,000 336,000
Share-based compensation expense - restricted stock units 211,000 211,000
Issuance of common stock upon the exercise of stock options  
Issuance of common stock upon the exercise of stock options, shares      
Issuance of common stock for vested restricted stock units $ 4,000 (4,000)
Issuance of common stock for vested restricted stock units, shares 400,000      
Net loss (1,791,000) (1,791,000)
Balance at Jan. 31, 2020 $ 800,000 125,245,000 (125,269,000) 776,000
Balance, shares at Jan. 31, 2020 79,994,402      
Balance at Oct. 31, 2019 $ 800,000 125,156,000 (124,603,000) 1,353,000
Balance, shares at Oct. 31, 2019 79,994,402      
Share-based compensation expense - stock options 68,000 68,000
Share-based compensation expense - restricted stock units 21,000 21,000
Issuance of common stock upon the exercise of stock options
Issuance of common stock upon the exercise of stock options, shares      
Net loss (666,000) (666,000)
Balance at Jan. 31, 2020 $ 800,000 125,245,000 (125,269,000) 776,000
Balance, shares at Jan. 31, 2020 79,994,402      
Balance at Jul. 31, 2020 $ 871,000 127,414,000 (123,474,000) 4,811,000
Balance, shares at Jul. 31, 2020 87,072,951      
Issuance of common stock in private placements, net
Issuance of common stock in private placements, net, shares      
Share-based compensation expense - stock options 428,000 428,000
Share-based compensation expense - restricted stock units 42,000 42,000
Issuance of common stock upon the exercise of stock options $ 2,000 (2,000)
Issuance of common stock upon the exercise of stock options, shares 150,190    
Issuance of common stock for vested restricted stock units
Issuance of common stock for vested restricted stock units, shares      
Net loss (775,000) (775,000)
Balance at Jan. 31, 2021 $ 873,000 127,882,000 (124,249,000) 4,506,000
Balance, shares at Jan. 31, 2021 87,223,141      
Balance at Oct. 31, 2020 $ 871,000 127,643,000 (123,654,000) 4,860,000
Balance, shares at Oct. 31, 2020 87,072,951      
Share-based compensation expense - stock options 220,000 220,000
Share-based compensation expense - restricted stock units 21,000 21,000
Issuance of common stock upon the exercise of stock options $ 2,000 (2,000)
Issuance of common stock upon the exercise of stock options, shares 150,190      
Net loss (595,000) (595,000)
Balance at Jan. 31, 2021 $ 873,000 $ 127,882,000 $ (124,249,000) $ 4,506,000
Balance, shares at Jan. 31, 2021 87,223,141      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Operating activities        
Net loss $ (595,000) $ (666,000) $ (775,000) $ (1,791,000)
Adjustments to reconcile net loss to net cash used in operating activities:        
Share-based compensation     470,000 547,000
Amortization of stock issued for services     4,000
Depreciation and amortization     90,000 100,000
Changes in operating assets and liabilities:        
Accounts receivable     623,000 217,000
Inventories     (71,000) 36,000
Prepaid expenses     (13,000) (1,000)
Accounts payable and accrued liabilities     (732,000) (46,000)
Deferred rent     (4,000)
Net cash used in operating activities     (408,000) (938,000)
Investing activities        
Purchases of property, plant and equipment     (504,000) (44,000)
Net cash used in investing activities     (504,000) (44,000)
Financing activities        
Net proceeds from the sale of common stock     830,000
Net cash provided by financing activities     830,000
Net decrease in cash, cash equivalents, and restricted cash     (912,000) (152,000)
Cash, cash equivalents, and restricted cash at beginning of period     3,914,000 473,000
Cash, cash equivalents, and restricted cash at end of period 3,002,000 321,000 3,002,000 321,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets        
Cash and cash equivalents 2,927,000 246,000 2,927,000 246,000
Restricted cash 75,000 75,000 75,000 75,000
Total cash, cash equivalents and restricted cash $ 3,002,000 $ 321,000 $ 3,002,000 321,000
Supplemental disclosure of non-cash activities        
Cash paid for taxes       $ 2,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Basis of Presentation
 6 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

1. Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended January 31, 2021 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2021. The July 31, 2020 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2020 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 8, 2020.

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Liquidity
 6 Months Ended
Jan. 31, 2021
Liquidity  
Liquidity

2. Liquidity

 

We have a history of recurring losses, and as of January 31, 2021 we have incurred a cumulative net loss of $124,249,000. During the six months ended January 31, 2021, we recorded a net loss of $775,000 on recorded net revenue of $2,507,000. In addition, we used $912,000 in operating and investing activities resulting in a cash balance of $2,927,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.

 

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

 

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies
 6 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

3. Significant Accounting Policies

 

Revenue Recognition

 

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

 

  1. Identify the contract with the customer
  2. Identify the performance obligations in the contract
  3. Determine the transaction price
  4. Allocate the transaction price to the performance obligations in the contract
  5. Recognize revenue when (or as) each performance obligation is satisfied

 

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.

 

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

 

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

 

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

 

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

 

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

 

Variable Consideration

 

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

 

Net Loss Per Share

 

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,748,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

 

Inventories consist of the following:

 

    January 31, 2021     July 31, 2020  
Raw materials   $ 20,000     $ 17,000  
Finished goods     598,000       530,000  
    $ 618,000     $ 547,000  

 

Share-Based Compensation

 

We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

 

Impairment of Long-Lived Assets

 

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.

 

Concentrations

 

Gross product sales. For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales. For the six months ended January 31, 2021, two customers accounted for 20% and 11% of our net product sales, respectively. For the three months ended January 31, 2020, two customers accounted for 14% and 10% of our net product sales, respectively. For the six months ended January 31, 2020, two customers accounted for 17% and 10% of our net product sales, respectively.

 

Accounts receivable. As of January 31, 2021, we had accounts receivable from one customer that comprised 31% of total accounts receivable. As of January 31, 2020, we had accounts receivable from three customers that comprised of 23%, 12% and 11% of total accounts receivable, respectively.

 

Purchases. For the three months ended January 31, 2021, two vendors accounted for 18% and 16% of our purchases, respectively. For the six months ended January 31, 2021, one vendor accounted for 39% of our purchases. For the three months ended January 31, 2020, one vendor accounted for 21% of our purchases. For the six months ended January 31, 2020, one vendor accounted for 21% of our purchases.

 

Accounts payable. As of January 31, 2021, our largest two vendors accounted for 35% and 13% of the total trade accounts payable, respectively. As of January 31, 2020, our largest two vendors accounted for 14% and 12% of the total accounts payable, respectively.

 

Segments

 

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Recent Accounting Pronouncements
 6 Months Ended
Jan. 31, 2021
Accounting Changes and Error Corrections [Abstract]  
Recent Accounting Pronouncements

4. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity
 6 Months Ended
Jan. 31, 2021
Stockholders' equity  
Stockholders' Equity

5. Stockholders’ Equity

 

Private Placement Financing – Fiscal Year 2020

 

On October 2, 2019, we entered into and completed a closing (the “Closing”) of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares of our common stock at a purchase price of $0.29 per share, the closing sales price of our common stock on the date prior to the Closing. The Shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer.

 

The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.

 

As of January 31, 2021, the Company had 327,765 warrants outstanding with exercise prices ranging from $1.25 to $1.28. All outstanding warrants will expire on or before January 23, 2022.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation
 6 Months Ended
Jan. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation

6. Share-Based Compensation

 

Restricted Stock Units

 

The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.

 

During the six months ended January 31, 2021, the Company recognized $42,000 of compensation cost relating to the shares vesting during the period. During the six month period ended January 31, 2020, the Company recognized $49,000 of compensation cost relating to the shares vesting during the period. In addition, the Company accelerated the vesting of 400,000 shares of stock issued to Henry R. Lambert with a remaining value of $162,000 upon his retirement during the period. In total, the Company recognized $211,000 from the vesting of these restricted stock units.

 

Of the 2,012,500 RSUs outstanding as of January 31, 2021, 1,512,500 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

 

During the six months ended January 31, 2021 there were no Restricted Stock Units granted. As of January 31, 2021, there was $185,000 of unrecognized non-cash compensation cost related to the remaining 500,000 RSUs we expect to vest, which will be recognized over a weighted average period of 2.24 years.

 

A summary of our restricted stock unit activity and related data is as follows:

 

Outstanding at July 31, 2020     2,012,500  
Granted     —  
Issued     —  
Forfeited     —  
Outstanding at January 31, 2021 (of which 1,512,500 have vested and are issuable)     2,012,500  

 

Stock Option Plans

 

2007 Equity Incentive Plan

 

In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 93,000 shares available for issuance under the 2007 Plan.

 

2017 Equity Incentive Plan

 

In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of January 31, 2021, there were approximately 5,121,000 shares available for issuance under the 2017 Plan.

 

During the six months ended January 31, 2021, the Compensation Committee of the Board of Directors authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term.

 

A summary of our stock option activity is as follows:

 

    Shares     Weighted-
Average
Exercise
Price		     Aggregate
Intrinsic
Value		  
Outstanding at July 31, 2020     9,432,875     $ 0.88     $ 5,255,000  
Granted     60,000     $ 1.30       —  
Exercised     (624,375 )   $ 0.88       170,000  
Expired     (60,000 )   $ 0.75       33,000  
Cancelled     (400,000 )   $ 1.19       —  
Outstanding at January 31, 2021     8,408,500     $ 0.87     $ 4,039,000  

 

The weighted-average remaining contractual term of options outstanding at January 31, 2021 was 5.0 years.

 

At January 31, 2021, options to purchase 7,073,500 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.90 and a weighted average remaining contractual term of 4.44 years. The total unrecognized compensation cost related to unvested stock option grants as of January 31, 2021 was approximately $385,000 and the weighted average period over which these grants are expected to vest is 0.92 years.

 

For the six months ended January 31, 2021 share-based compensation expense for stock options was $428,000. For the six months ended January 31, 2020 share-based compensation expense for stock options was $336,000.

 

During the six months ended January 31, 2021, there was a net exercise on 624,375 stock options which resulted in the issuance of 150,190 shares of our common stock. As these options were net exercised, as permitted under the respective option agreements, we did not receive any cash proceeds.

 

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

 

   

Three

Months Ended January 31, 2021

    

Three

Months Ended January 31, 2020

    

Six

Months Ended January 31, 2021

    

Six

Months Ended January 31, 2020

  
Volatility     104.93 %     79.48 %     104.93. %     79.62 %
Risk-free interest rate     0.18 %     1.46 %     0.18 %     1.43 %
Dividend yield     0.0 %     0.0 %     0.0 %     0.0 %
Expected life     2.81 years       5.50       2.81 years       5.57 years  

 

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

 

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

 

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

 

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Related Party Transactions
 6 Months Ended
Jan. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

7. Related Party Transactions

 

As of January 31, 2021 and January 31, 2020, accounts payable include $64,047 and $120,000 in board fees due to officers and directors, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies
 6 Months Ended
Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

8. Commitments and Contingencies

 

The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

 

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

 

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Revenue Recognition

Revenue Recognition

 

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

 

  1. Identify the contract with the customer
  2. Identify the performance obligations in the contract
  3. Determine the transaction price
  4. Allocate the transaction price to the performance obligations in the contract
  5. Recognize revenue when (or as) each performance obligation is satisfied

 

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

 

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.

 

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

 

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

 

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

 

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

 

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

 

Variable Consideration

 

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.
Use of Estimates

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.
Net Loss Per Share

Net Loss Per Share

 

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,748,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.
Inventory

Inventory

 

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

 

Inventories consist of the following:

 

    January 31, 2021     July 31, 2020  
Raw materials   $ 20,000     $ 17,000  
Finished goods     598,000       530,000  
    $ 618,000     $ 547,000  
Share-Based Compensation

Share-Based Compensation

 

We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2021 and 2020, no impairment of long-lived assets was indicated or recorded
Concentrations

Concentrations

 

Gross product sales. For the three months ended January 31, 2021, three individual customers accounted for 15%, 14% and 12% of our net product sales. For the six months ended January 31, 2021, two customers accounted for 20% and 11% of our net product sales, respectively. For the three months ended January 31, 2020, two customers accounted for 14% and 10% of our net product sales, respectively. For the six months ended January 31, 2020, two customers accounted for 17% and 10% of our net product sales, respectively.

 

Accounts receivable. As of January 31, 2021, we had accounts receivable from one customer that comprised 31% of total accounts receivable. As of January 31, 2020, we had accounts receivable from three customers that comprised of 23%, 12% and 11% of total accounts receivable, respectively.

 

Purchases. For the three months ended January 31, 2021, two vendors accounted for 18% and 16% of our purchases, respectively. For the six months ended January 31, 2021, one vendor accounted for 39% of our purchases. For the three months ended January 31, 2020, one vendor accounted for 21% of our purchases. For the six months ended January 31, 2020, one vendor accounted for 21% of our purchases.

 

Accounts payable. As of January 31, 2021, our largest two vendors accounted for 35% and 13% of the total trade accounts payable, respectively. As of January 31, 2020, our largest two vendors accounted for 14% and 12% of the total accounts payable, respectively.
Segments

Segments

 

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Schedule of Inventories

Inventories consist of the following:

 

    January 31, 2021     July 31, 2020  
Raw materials   $ 20,000     $ 17,000  
Finished goods     598,000       530,000  
    $ 618,000     $ 547,000  
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Tables)
 6 Months Ended
Jan. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Activity

A summary of our restricted stock unit activity and related data is as follows:

 

Outstanding at July 31, 2020     2,012,500  
Granted     —  
Issued     —  
Forfeited     —  
Outstanding at January 31, 2021 (of which 1,512,500 have vested and are issuable)     2,012,500  
Schedule of Stock Option Activity

A summary of our stock option activity is as follows:

 

    Shares     Weighted-
Average
Exercise
Price		     Aggregate
Intrinsic
Value		  
Outstanding at July 31, 2020     9,432,875     $ 0.88     $ 5,255,000  
Granted     60,000     $ 1.30       —  
Exercised     (624,375 )   $ 0.88       170,000  
Expired     (60,000 )   $ 0.75       33,000  
Cancelled     (400,000 )   $ 1.19       —  
Outstanding at January 31, 2021     8,408,500     $ 0.87     $ 4,039,000  
Schedule of Fair Value Assumptions

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

 

   

Three

Months Ended January 31, 2021

    

Three

Months Ended January 31, 2020

    

Six

Months Ended January 31, 2021

    

Six

Months Ended January 31, 2020

  
Volatility     104.93 %     79.48 %     104.93. %     79.62 %
Risk-free interest rate     0.18 %     1.46 %     0.18 %     1.43 %
Dividend yield     0.0 %     0.0 %     0.0 %     0.0 %
Expected life     2.81 years       5.50       2.81 years       5.57 years  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Liquidity (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Jul. 31, 2020
Liquidity          
Cumulative net loss $ (124,249,000)   $ (124,249,000)   $ (123,474,000)
Net income (loss) (595,000) $ (666,000) (775,000) $ (1,791,000)  
Revenue 916,000 2,507,000  
Cash balance     (912,000) (152,000)  
Cash and cash equivalents $ 2,927,000 $ 246,000 $ 2,927,000 $ 246,000 $ 3,839,000
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Dilutive common share     10,748,765 10,410,890
Impairment of long-lived assets
Customer Concentration Risk [Member] | Net Product Sales [Member] | Individual Customer One [Member]        
Concentration risk percentage 15.00%      
Customer Concentration Risk [Member] | Net Product Sales [Member] | Individual Customer Two [Member]        
Concentration risk percentage 14.00%      
Customer Concentration Risk [Member] | Net Product Sales [Member] | Individual Customer Three [Member]        
Concentration risk percentage 12.00%      
Customer Concentration Risk [Member] | Net Product Sales [Member] | Customer One [Member]        
Concentration risk percentage   14.00% 20.00% 17.00%
Customer Concentration Risk [Member] | Net Product Sales [Member] | Customer Two [Member]        
Concentration risk percentage   10.00% 11.00% 10.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]        
Concentration risk percentage     31.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]        
Concentration risk percentage       23.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]        
Concentration risk percentage       12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]        
Concentration risk percentage       11.00%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor One [Member]        
Concentration risk percentage 18.00% 21.00% 39.00% 21.00%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor Two [Member]        
Concentration risk percentage 16.00%      
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor One [Member]        
Concentration risk percentage     35.00% 14.00%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor Two [Member]        
Concentration risk percentage     13.00% 12.00%
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)
Jan. 31, 2021
Jul. 31, 2020
Accounting Policies [Abstract]    
Raw materials $ 20,000 $ 17,000
Finished goods 598,000 530,000
Inventory, net $ 618,000 $ 547,000
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity (Details Narrative) - USD ($)
 6 Months Ended
Oct. 02, 2019
Jan. 31, 2021
Jan. 31, 2020
Value of common stock shares   $ 830,000
Number of warrants outstanding   327,765  
Warrant expiration date   Jan. 23, 2022  
Minimum [Member]      
Warrant exercise price   $ 1.25  
Maximum [Member]      
Warrant exercise price   $ 1.28  
Private Placement [Member]      
Value of common stock shares $ 830,000    
Number of common stock shares issued 2,862,068    
Price per share $ 0.29    
Proceeds from issuance of private placement $ 830,000    
Tom Y Lee [Member] | Private Placement [Member]      
Investments amount 290,000    
Dale Okuno [Member] | Private Placement [Member]      
Investments amount $ 250,000    
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Feb. 29, 2016
Jan. 31, 2021
Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation, vesting period   11 months 1 day  
Number of units, vested   500,000  
Unrecognized non-cash compensation costs   $ 385,000  
Options issued to purchase common stock exercisable   7,073,500  
Weighted average exercise price   $ 0.90  
Weighted average contractual term   4 years 5 months 9 days  
Share-based compensation   $ 428,000 $ 336,000
2007 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation, vesting period 10 years    
Common stock shares increase under the plan 4,000,000    
Share-based compensation, expiration date Feb. 04, 2026    
Number of shares available for issuance under the plan   93,000  
2017 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation, vesting period   10 years  
Weighted-average contractual term of expected to vest   5 years  
Share-based compensation, expiration date   Jan. 31, 2031  
Number of shares available for issuance under the plan   5,121,000  
Common stock, shares reserved   5,000,000  
Options issued to purchase common stock exercisable   624,375  
Number of common stock shares issued   150,190  
Consultant [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of stock option authorized for issuance   60,000  
Fair value of stock option   $ 48,000  
Terms of award   The options vest quarterly over one year and carry a five year term.  
Restricted Stock Unit Awards (RSU's) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation, vesting period   2 years  
Compensation cost recognized   $ 211,000  
Number of units, unvested   2,012,500  
Number of units, vested   1,512,500  
Restricted stock units vested description   These RSUs are issued upon settlement date which is defined as "for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code".  
Number of units, granted    
Unrecognized non-cash compensation costs   $ 185,000  
Restricted Stock Unit Awards (RSU's) [Member] | Vested and Issuable [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of units, vested   1,512,500  
Weighted-average contractual term of expected to vest   2 years 2 months 27 days  
Restricted Stock Unit Awards (RSU's) [Member] | Shares Vested During Period [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Compensation cost recognized   $ 42,000 $ 49,000
Restricted Stock Unit Awards (RSU's) [Member] | Henry R. Lambert [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Compensation cost recognized   $ 162,000  
Stock issued during period, shares, share-based compensation   400,000  
Restricted Stock Unit Awards (RSU's) [Member] | Consultants and Others [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation, vesting period   10 years  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Restricted Stock Activity (Details) - Restricted Stock Unit Awards (RSU's) [Member]
 6 Months Ended
Jan. 31, 2021
shares
Outstanding, Beginning balance 2,012,500
Granted
Issued
Forfeited
Outstanding, Ending balance 2,012,500
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical)
 6 Months Ended
Jan. 31, 2021
shares
Number of units, vested and issuable 500,000
Restricted Stock Unit Awards (RSU's) [Member]  
Number of units, vested and issuable 1,512,500
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)
 6 Months Ended
Jan. 31, 2021
Share-based Payment Arrangement [Abstract]  
Options Outstanding Shares, Beginning Balance 9,432,875
Options Granted, Shares 60,000
Options Exercised, Shares
Options Expired, Shares (60,000)
Options Cancelled, Shares (400,000)
Options Outstanding Shares, Ending Balance 8,408,500
Weighted- Average Exercise Price Outstanding, Beginning Balance $ 0.88
Weighted- Average Exercise Price Granted 1.30
Weighted- Average Exercise Price Exercised 0.88
Weighted- Average Exercise Price Expired 0.75
Weighted- Average Exercise Price Cancelled 1.19
Weighted- Average Exercise Price Outstanding, Ending Balance $ 0.87
Aggregate Intrinsic Value Outstanding, Beginning Balance $ 5,255,000
Aggregate Intrinsic Value Outstanding, Exercised 170,000
Aggregate Intrinsic Value Outstanding, Expired 33,000
Aggregate Intrinsic Value Outstanding, Ending Balance $ 4,039,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation - Schedule of Fair Value Assumptions (Details)
 3 Months Ended 6 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Share-based Payment Arrangement [Abstract]        
Volatility 104.93% 79.48% 104.93% 79.62%
Risk-free interest rate 0.18% 1.46% 0.18% 1.43%
Dividend yield 0.00% 0.00% 0.00% 0.00%
Expected life 2 years 9 months 22 days 5 years 6 months 2 years 9 months 22 days 5 years 6 months 25 days
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Related Party Transactions (Details Narrative) - USD ($)
Jan. 31, 2021
Jul. 31, 2020
Jan. 31, 2020
Accounts payable $ 617,000 $ 1,344,000  
Board Fees due to Officers and Directors [Member]      
Accounts payable $ 64,047   $ 120,000
EXCEL 39 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 93 237 1 false 34 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://purebio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://purebio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://purebio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://purebio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://purebio.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://purebio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://purebio.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://purebio.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://purebio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Recent Accounting Pronouncements Sheet http://purebio.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://purebio.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Share-Based Compensation Sheet http://purebio.com/role/Share-basedCompensation Share-Based Compensation Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://purebio.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://purebio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://purebio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://purebio.com/role/SignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://purebio.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables 16 false false R17.htm 00000017 - Disclosure - Share-Based Compensation (Tables) Sheet http://purebio.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://purebio.com/role/Share-basedCompensation 17 false false R18.htm 00000018 - Disclosure - Liquidity (Details Narrative) Sheet http://purebio.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://purebio.com/role/Liquidity 18 false false R19.htm 00000019 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies - Schedule of Inventories (Details) Sheet http://purebio.com/role/SignificantAccountingPolicies-ScheduleOfInventoriesDetails Significant Accounting Policies - Schedule of Inventories (Details) Details 20 false false R21.htm 00000021 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://purebio.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://purebio.com/role/StockholdersEquity 21 false false R22.htm 00000022 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://purebio.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://purebio.com/role/Share-basedCompensationTables 22 false false R23.htm 00000023 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfRestrictedStockActivityDetails Share-Based Compensation - Schedule of Restricted Stock Activity (Details) Details 23 false false R24.htm 00000024 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfRestrictedStockActivityDetailsParenthetical Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical) Details 24 false false R25.htm 00000025 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfStockOptionActivityDetails Share-Based Compensation - Schedule of Stock Option Activity (Details) Details 25 false false R26.htm 00000026 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfFairValueAssumptionsDetails Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Details 26 false false R27.htm 00000027 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://purebio.com/role/RelatedPartyTransactions 27 false false All Reports Book All Reports pure-20210131.xml pure-20210131.xsd pure-20210131_cal.xml pure-20210131_def.xml pure-20210131_lab.xml pure-20210131_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 44 0001493152-21-006001-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-006001-xbrl.zip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�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end